-
1 week ago | 
dcjournal.com | Ross Marchand
Uncertainty surrounds the Food and Drug Administration, where personnel cuts are hampering drug approvals and mixed messages abound. It’s unclear whether FDA Commissioner Marty Makary wants to speed up approvals, slow them down, or an unsettling combination of the two. Artificial intelligence has the potential to significantly bolster agency efficiency, and the FDA is poised to roll out AI quickly and aggressively.
-
2 weeks ago | 
gopostal.substack.com | Ross Marchand
The Hill’s Elizabeth Crisp reports,House Democrats are seeking more information and a face-to-face briefing from the U.S. Postal Service about the Trump administration’s use of Postal Inspection Service (USPIS) officers to aid the Department of Homeland Security (DHS) with President Trump’s immigration crackdown.
-
2 weeks ago | 
detroitnews.com | Ross Marchand
Ross MarchandView Comments It’s tempting to view e-commerce companies like Amazon and search engines like Google as corporate behemoths that need to be cut down to size. That perception, which has fueled boycotts, antitrust efforts and dubious regulatory classifications, falls apart on a closer look. The truth is that Amazon and other leading companies would be nothing without a diverse array of partnerships with small businesses, which drive sales and offer consumers many options.
-
2 weeks ago | 
fredericknewspost.com | Ross Marchand
It’s tempting to view e-commerce companies like Amazon and search engines like Google as corporate behemoths that need to be cut down to size. That perception, which has fueled boycotts, antitrust efforts and dubious regulatory classifications, falls apart on a closer look. The truth is that Amazon and other leading companies would be nothing without a diverse array of partnerships with small businesses, which drive sales and offer consumers many options.
-
3 weeks ago | 
dcjournal.com | Ross Marchand
It’s tempting to view e-commerce companies like Amazon and search engines like Google as corporate behemoths that need to be cut down to size. That perception, which has fueled boycotts, antitrust efforts and dubious regulatory classifications, falls apart on a closer look. The truth is that Amazon and other leading companies would be nothing without a diverse array of partnerships with small businesses, which drive sales and offer consumers many options.
-
3 weeks ago | 
wvgazettemail.com | Ross Marchand
The Trump administration is laudably committed to rooting out waste across the federal government and axing large and ineffective programs. There are some early encouraging signs that the Food and Drug Administration will reduce spending and needless red tape in line with the administration’s government-wide push. For example, FDA Commissioner Marty Makary has pledged to create an expedited pathway for approving therapies for rare diseases and to use artificial intelligence to expedite approvals.
-
3 weeks ago | 
issuesinsights.com | Ross Marchand
People are accustomed to long and unnecessary doctor’s visits to receive a diagnosis and then have a prescription given to them. The process is tedious, costly, and in some cases, unnecessary. That old dynamic may be changing, as many come to realize the absurdity of locking away therapies behind the counter. Recently, health care and biotech writer Alex Kesin wrote to Department of Health and Human Services Secretary Robert F.
-
4 weeks ago | 
grandforksherald.com | Ross Marchand
The Trump administration is laudably committed to rooting out waste across the federal government and axing large and ineffective programs. There are some early encouraging signs that the Food and Drug Administration will reduce spending and needless red tape in line with the administration’s government-wide push.
-
4 weeks ago | 
latrobebulletinnews.com | Ross Marchand
The Trump administration is laudably committed to rooting out waste across the federal government and axing large and ineffective programs. There are some early encouraging signs that the Food and Drug Administration will reduce spending and needless red tape in line with the administration’s government-wide push. For example, FDA Commissioner Marty Makary has pledged to create an expedited pathway for approving therapies for rare diseases and to use artificial intelligence to expedite approvals.
-
4 weeks ago | 
bostonherald.com | Ross Marchand
The Trump administration is laudably committed to rooting out waste across the federal government and axing large and ineffective programs. There are some early encouraging signs that the Food and Drug Administration will reduce spending and needless red tape in line with the administration’s government-wide push. For example, FDA Commissioner Marty Makary has pledged to create an expedited pathway for approving therapies for rare diseases and to use artificial intelligence to expedite approvals.
